openPR Logo
Press release

Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market Estimated to Flourish by 2017 – 2025 : Persistence Market Research

06-16-2017 03:22 PM CET | Health & Medicine

Press release from: Persistence Market Research

Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market

Lambert-Eaton Myasthenic Syndrome (LEMS) exceptional autoimmune syndrome involving improper transmission at neuromuscular junction with the key clinical symptom of muscle weakness. Weakness in muscles in LEMS is caused due to autoantibodies to voltage gated calcium channels resulting in reduction of acetylcholine released from terminals of the nerve. The necessary knowledge of elusive clinical features and laboratory oddities makes the early identification of LEMS possible. Early detection of LEMS is principally significant due to its strong correlation with small cell lung cancer (SCLC). Even though LEMS can arise at any point in the path of SCLC, it serves as a marker for early detection of the disease, and thus permits better opportunity for treatment of such malignancy. Patients with LEMS should be examined and then treated by both a neurologist and if appropriate, an oncologist. In case of the diagnosis the principal concern must be appropriate treatment of malignancy. Treatment of LEMS includes immunosuppressant agents, but success of the treatment depends on toxicity and trouble involved in administering the therapy.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/13732

Treatment of LEMS involves various approaches that include reducing the amount of antibodies so as to improve the muscle function, increasing the acetylcholine quantity received by the muscles, increasing the overall acetylcholine released in the body and other mechanism which are not approved in all the regions. The therapy involving reduction in the amount of antibodies comprises of corticosteroids, cyclosporine, azathioprine, monoclonal antibodies and many more. The therapy involving the amount of acetylcholine reception by the muscles comprises of Cholinesterase inhibitors. The therapy involving the increased amount of acetylcholine production in the body comprises of aminopyridines. There is a drug which treats the disorder but those are not approved in all the regions. This category includes amifampridine which is approved only in European countries.

The Global Lambert Eaton Myasthenic Syndrome (LEMS) Therapeutics market can be segmented by Treatment type, Disease Type, Distribution Channel and Region.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/13732

Geographically, the North America are anticipated to be most lucrative market during the forecast period, mainly owing to high prevalence of the disease and better reimbursement policies. Moreover the existence of several drug manufacturers and growing amount of clinical research is anticipated to promote rapid market growth in this region. Asia Pacific region is anticipated to observe high market development followed by North America and Europe mostly owing to patient population and better and affordable therapy options by the companies operating in this market. The large patient pool and refining distribution channel in the region is also likely to lift the LEMS market. Latin America and Middle East and Africa are anticipated to follow owing to growing government expenditure on the healthcare.

Some of the major players in the global LEMS therapeutic market are Catalyst Pharmaceuticals, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Allergan, Plc, Novartis International AG, F. Hoffmann-La Roche AG, Biomarin Pharmaceutical Inc.

To view complete report @ http://www.persistencemarketresearch.com/market-research/lambert-eaton-myasthenic-syndrome-therapeutics-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
 

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market Estimated to Flourish by 2017 – 2025 : Persistence Market Research here

News-ID: 582805 • Views:

More Releases from Persistence Market Research

Orthopedic Trauma Devices Market Booming, Projected to Reach US$ 17.5 billion by 2032, Expanding at a CAGR of 6.2% - PMR Report
Orthopedic Trauma Devices Market Booming, Projected to Reach US$ 17.5 billion by …
The global orthopedic trauma devices market is estimated to reach a size of US$ 11.5 billion in 2025 and is predicted to rise at a CAGR of 6.2% through the assessment period, reaching a projected value of US$ 17.5 billion by 2032. 🔗Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/2895 Market Overview and Growth Drivers The orthopedic trauma devices industry is witnessing steady growth,
Boom in Medical Tapes Market Driven by Rising Healthcare Demand Through 2032
Boom in Medical Tapes Market Driven by Rising Healthcare Demand Through 2032
The global medical tapes market is gaining traction, underpinned by increasing demand across a variety of healthcare applications. According to a recent report by Persistence Market Research, the market is projected to be valued at approximately US$ 2.3 billion in 2025, and is forecast to grow to around US$ 3.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of about 6.1% during 2025-2032. Request a Sample: https://www.persistencemarketresearch.com/samples/3435 Market Size
MENA Infant Milk Formula Market to Reach US$6.5 Bn by 2032 Driven by Nutrition Awareness & Workforce Growth
MENA Infant Milk Formula Market to Reach US$6.5 Bn by 2032 Driven by Nutrition A …
The MENA infant milk formula market is poised for significant expansion over the next decade, reflecting broader changes in lifestyle patterns, consumer awareness, and evolving family structures. The market size is likely to be valued at US$3.7 billion in 2025 and is projected to reach US$6.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.4% during the forecast period (2025-2032). This robust growth trajectory is primarily
High Oleic Oil Market to Reach US$19.5 Bn by 2032, Driven by Health and Food Industry Demand
High Oleic Oil Market to Reach US$19.5 Bn by 2032, Driven by Health and Food Ind …
The global high oleic oil market is set to witness substantial expansion over the coming years. Valued at US$12.7 billion in 2025, the market is projected to reach US$19.5 billion by 2032, growing at a steady CAGR of 6.3% during the forecast period from 2025 to 2032. The rising demand for healthier edible oils with improved stability, extended shelf life, and superior nutritional properties has positioned high oleic oils as

All 5 Releases


More Releases for LEMS

Lambert-Eaton Myasthenic Syndrome (LEMS) Market to Set Phenomenal Growth From 20 …
Introduction Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder that disrupts communication between nerves and muscles, leading to muscle weakness, fatigue, and autonomic dysfunction. It is often associated with underlying malignancies, particularly small-cell lung cancer (SCLC), but can also occur independently. Because of its rarity and overlap with other neuromuscular conditions, LEMS is frequently underdiagnosed or misdiagnosed, delaying treatment initiation. The growing focus on rare diseases, rising global adoption of orphan
Lambert-Eaton Myasthenic Syndrome (LEMS) Market to Reach USD 280 Million by 2034
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs, fatigue, and autonomic dysfunction. It occurs when antibodies target voltage-gated calcium channels (VGCCs) at the neuromuscular junction, impairing acetylcholine release. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71907 Approximately 50-60% of LEMS cases are paraneoplastic, most often associated with small-cell lung cancer (SCLC). The remainder are autoimmune and non-cancer related. LEMS remains underdiagnosed
Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market Forecast over 2017 …
Some of the key players operating the global laser diffraction equipment market are Malvern Instruments Ltd, HORIBA, Ltd, Fritsch GmbH, Shimadzu Corporation, Beckman Coulter, Inc., Micrometrics Instrument Corporation, Angstrom Advanced Inc., Sympatc GmbH among others worldwide. To maintain a significant position in the global laser diffraction equipment market some of the major players are operating strategies like investment in R and D sector to broaden their product portfolios. The players are
Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market: Key Players, Growt …
Lambert-Eaton Myasthenic Syndrome (LEMS) exceptional autoimmune syndrome involving improper transmission at neuromuscular junction with the key clinical symptom of muscle weakness. Weakness in muscles in LEMS is caused due to autoantibodies to voltage gated calcium channels resulting in reduction of acetylcholine released from terminals of the nerve. The necessary knowledge of elusive clinical features and laboratory oddities makes the early identification of LEMS possible. Early detection of LEMS is principally
Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Marke to Rear Excessive Gr …
Lambert-Eaton Myasthenic Syndrome (LEMS) exceptional autoimmune syndrome involving improper transmission at neuromuscular junction with the key clinical symptom of muscle weakness. Weakness in muscles in LEMS is caused due to autoantibodies to voltage gated calcium channels resulting in reduction of acetylcholine released from terminals of the nerve. The necessary knowledge of elusive clinical features and laboratory oddities makes the early identification of LEMS possible. Early detection of LEMS is principally
Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market to Register Steady …
Lambert-Eaton Myasthenic Syndrome (LEMS) exceptional autoimmune syndrome involving improper transmission at neuromuscular junction with the key clinical symptom of muscle weakness. Weakness in muscles in LEMS is caused due to autoantibodies to voltage gated calcium channels resulting in reduction of acetylcholine released from terminals of the nerve. The necessary knowledge of elusive clinical features and laboratory oddities makes the early identification of LEMS possible. Early detection of LEMS is principally